CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes

被引：0
|
作者：
J-F Lesesve
M Debouverie
M Decarvalho Bittencourt
M-C Béné
机构：
[1] Laboratory of Hematology,Neurology department
[2] University Hospital,undefined
[3] University Hospital,undefined
[4] Laboratory of Immunology,undefined
[5] University Hospital,undefined
来源：
Bone Marrow Transplantation | 2011年 / 46卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1489 / 1491
页数：2
相关论文
共 50 条
  • [1] CD49d blockade by natalizumab therapy in patients with multiple sclerosis increases immature B-lymphocytes
    Lesesve, J-F
    Debouverie, M.
    Bittencourt, M. Decarvalho
    Bene, M-C
    BONE MARROW TRANSPLANTATION, 2011, 46 (11) : 1489 - 1491
  • [2] Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients
    Punet-Ortiz, Joan
    Vicente Hervas-Garcia, Jose
    Teniente-Serra, Aina
    Cano-Orgaz, Antonio
    Jose Mansilla, Maria
    Quirant-Sanchez, Bibiana
    Navarro-Barriuso, Juan
    Fernandez-Sanmartin, Marco A.
    Presas-Rodriguez, Silvia
    Ramo-Tello, Cristina
    Maria Martinez-Caceres, Eva
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2018, 94 (02) : 327 - 333
  • [3] CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function
    D Jing
    U Oelschlaegel
    R Ordemann
    K Hölig
    G Ehninger
    H Reichmann
    T Ziemssen
    M Bornhäuser
    Bone Marrow Transplantation, 2010, 45 : 1489 - 1496
  • [4] CD49d blockade by natalizumab in patients with multiple sclerosis impacts on steady-state haematapoiesis and mobilises progenitors with a distinct phenotype and function
    Bornhaeuser, M.
    Jing, D.
    Oelschlaegel, U.
    Ordemann, R.
    Reichmann, H.
    Ehininger, G.
    Ziemssen, T.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S136
  • [5] CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function
    Jing, D.
    Oelschlaegel, U.
    Ordemann, R.
    Hoelig, K.
    Ehninger, G.
    Reichmann, H.
    Ziemssen, T.
    Bornhaeuser, M.
    BONE MARROW TRANSPLANTATION, 2010, 45 (10) : 1489 - 1496
  • [6] CD49D EXPRESSION ON T LYMPHOCYTES AND CD8 EFFECTOR PERCENTAGE AS PREDICTORS OF JC VIRUS REACTIVATION IN MULTIPLE SCLEROSIS PATIENTS ON NATALIZUMAB TREATMENT
    Iannetta, M.
    Zingaropoli, M. A.
    Bellizzi, A.
    Anzivino, E.
    D'Abramo, A.
    Oliva, A.
    Morreale, M.
    Pontecorvo, S.
    Lo Menzo, S.
    Pietropaolo, V.
    Francia, A.
    Mastroianni, C. M.
    Vullo, V.
    Ciardi, M. R.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2016, 36 : 254 - 254
  • [7] Natalizumab treatment alters microRNA expression in B-lymphocytes in multiple sclerosis patients
    Sievers, C.
    Meira, M.
    Hoffmann, F.
    Fontoura, P.
    Kappos, L.
    Lindberg, R. L. P.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S127 - S128
  • [8] VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis
    Muraro, PA
    Leist, T
    Bielekova, B
    McFarland, HF
    JOURNAL OF NEUROIMMUNOLOGY, 2000, 111 (1-2) : 186 - 194
  • [9] Monitoring of expression of two CD49d epitopes as biomarker during natalizumab therapy
    Johanson, R.
    Leist, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 457 - 457
  • [10] Effect of natalizumab on B lymphocytes in patients with multiple sclerosis
    Putzki, N.
    Kumar, M.
    Grosse-Wilde, H.
    Kreuzfelder, E.
    MULTIPLE SCLEROSIS, 2007, 13 : S158 - S158
12345